NCT06357754 2026-01-22Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary MalignancyBristol-Myers SquibbRecruiting50 enrolled